Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: A systematic review.

Background: Immunomodulatory strategies in heparin-induced thrombocytopenia (HIT) include the use of intravenous immune globulin (IVIG) and therapeutic plasma exchange (TPE). The optimal application of these therapies is unknown and outcomes data are limited. We investigated treatment categories and laboratory and clinical outcomes of IVIG and/or TPE in HIT with a systematic literature review.

Alternatives to Transfusion.

Objectives: We discuss two main categories of blood substitutes: perfluorocarbons and hemoglobin-based oxygen carriers.

Methods: We provide a review of the notable products developed in both categories and include their attributes as well as their setbacks.

Results: We contribute a case report tothe growing literature of the successful use of Sanguinate.

Experience with uncrossmatched blood refrigerator in emergency department.

Background: Uncrossmatched packed red blood cell (PRBC) transfusion is fundamental in resuscitation of hemorrhagic shock. Ready availability of uncrossmatched blood can be achieved by storing uncrossmatched blood in a blood bank refrigerator in the emergency department (ED), but could theoretically lead to inappropriate uncrossmatched use.

Methods: This retrospective study was performed at a level I trauma center from January 2013 to March 2014.

Hemostasis testing and therapeutic plasma exchange: Results of a practice survey.

Introduction: Performing therapeutic plasma exchange (TPE) with albumin replacement decreases coagulation factor and platelet levels. No defined guidelines exist regarding laboratory testing to assess hemostasis in patients undergoing TPE.

Materials And Methods: A survey to evaluate hemostasis testing with TPE was distributed using online survey software.

Hemostasis management and therapeutic plasma exchange: Results of a practice survey.

Background: Patients undergoing therapeutic plasma exchange (TPE) may present with risks for hemorrhage or thrombosis. Use of replacement fluids devoid of coagulation factors will decrease factor levels and platelet levels. There are no established guidelines for hemostasis management in these situations.